Development of Oral Azacitidine With Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including Chronic Myelomonocytic Leukemia (CMML) by Targeting Pharmacokinetic AUC Equivalence vs Subcutaneous Azacitidine

被引：0
|
作者：
Garcia-Manero, Guillermo [1 ]
McCloskey, James [2 ]
Scott, Bart L. [3 ]
Griffiths, Elizabeth A. [4 ]
Kiner-Strachan, Bonnie [5 ]
Roboz, Gail J. [6 ,7 ]
Meyer, Janelle [8 ]
Chan, Winny [9 ]
Sano, Yuri [9 ]
Oganesian, Aram [9 ]
Keer, Harold K. [9 ]
Savona, Michael R. [10 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Hackensack Med Ctr, John Thuerer Canc Ctr, Hackensack, NJ USA
[3] Fred Hutchinson Canc Ctr, Seattle, WA USA
[4] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
[5] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[6] Weill Cornell Med, New York, NY USA
[7] NewYork Presbyterian Hosp, New York, NY USA
[8] Oregon Oncol Specialists, Salem, OR USA
[9] Taiho Oncol Inc, Pleasanton, CA USA
[10] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
MDS; ASTX030; azacitidine; cedazuridine; oral hypomethylating agents; myelodysplastic syndromes; CMML;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MDS-773
引用
收藏
页码：S406 / S407
页数：2
相关论文
共 42 条
  • [31] Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)
    Kadia, Tapan M.
    Benton, Christopher
    Erba, Harry P.
    Gandhi, Mitul
    Levy, Moshe Y.
    Percival, Mary-Elizabeth M.
    Ulrickson, Matthew
    Yimer, Habte
    Yu, Min
    Chen, Zi
    Wang, Jing
    Li, Mingyu
    Ahmad, Mohammad
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2022, 140 : 11659 - 11660
  • [32] A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), Results From a Phase 1 Study
    MacBeth, Kyle J.
    Laille, Eric
    Ning, Yuhong
    Cogle, Christopher R.
    Skikne, Barry
    Gore, Steven D.
    Garcia-Manero, Guillermo
    Ward, M. Renee
    BLOOD, 2009, 114 (22) : 705 - 705
  • [33] Phase II study of pevonedistat (P) plus azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777).
    Ades, Lionel
    Watts, Justin M.
    Radinoff, Atanas
    Arnan, Montserrat
    Cerrano, Marco
    Font Lopez, Patricia
    Zeidner, Joshua F.
    Diez-Campelo, Maria
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolay
    Fram, Robert J.
    Zhao, Dan
    Faller, Douglas, V
    Sekeres, Mikkael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine
    Field, Teresa
    Perkins, Janelle
    Tomblyn, Marcie
    Hillgruber, Ryan
    Nishihori, Taiga
    Mishra, Asmita
    Pidala, Joseph
    Ayala, Ernesto
    Locke, Frederick L.
    Alsina, Melissa
    Betts, Brian C.
    Padron, Eric
    Fernandez, Hugo F.
    Lancet, Jeffrey E.
    List, Alan
    Komrokji, Rami S.
    Kharfan-Dabaja, Mohamed A.
    Anasetti, Claudio
    BLOOD, 2013, 122 (21)
  • [35] An Open-Label, Multicenter, Phase Ib Study of the Anti-TIM3 Monoclonal Antibody BC3402 in Combination with Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
    Li, Bing
    Yin, Qing-song
    Yan, Xiaojing
    Hang, Min
    Guo, Hai-Jun
    Wang, Sheng
    Wang, Yi-wei
    Hei, Yong-jiang
    Xiao, Zhi-jian
    BLOOD, 2024, 144 : 4135 - 4136
  • [36] Phase 3 study of first line pevonedistat (PEV) plus azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML).
    Sekeres, Mikkael A.
    Fram, Robert J.
    Hua, Zhaowei
    Ades, Lionel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] Phase 3b Study Design for a Comparison of Treatment Preference between Oral Decitabine/Cedazuridine and Azacitidine in Adult Patients with IPSS-R Intermediate Myelodysplastic Syndrome, IPSS Intermediate-2 or High-Risk Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukaemia, or Chronic Myelomonocytic Leukaemia
    Enjeti, Anoop K.
    Fong, Chun Yew
    Castaldi, Francesco
    van Wyk, Greg
    Walton, Richard
    Paine, Taliesha
    Keer, Harold N.
    BLOOD, 2023, 142
  • [38] Pevonedistat (PEV) plus Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 2030% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)
    Sekeres, Mikkael A.
    Girshova, Larisa
    Doroni, Vadim A.
    Diez-Campelo, Maria
    Valcarcel, David
    Kambhampati, Suman
    Viniou, Nora-Athina
    Woszczyk, Dariusz
    De Paz Arias, Raquel
    Symeonidis, Argiris
    Anagnostopoulos, Achilles
    Munhoz, Eduardo Ciliao
    Platzbecker, Uwe
    Santini, Valeria
    Fram, Robert J.
    Yuan, Ying
    Faller, Douglas V.
    Ades, Lionel
    BLOOD, 2021, 138
  • [39] A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 (Lacutoclax) As Monotherapy and in Combination with Azacitidine in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
    Burgues, Juan Miguel Bergua
    Koenig, Kristin
    Montesinos, Pau
    Bixby, Dale L.
    Burke, Patrick W.
    Daver, Naval
    Anthony, Stephen P.
    Tan, Fenlai
    Chen, Yi
    Chen, Yu
    Aviles, Ignacio Casas
    Curran, Emily K.
    BLOOD, 2024, 144 : 6009 - 6010
  • [40] A Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202)
    Borthakur, Gautam
    Jonas, Brian A.
    Roberts-Thomson, Emily L.
    Michelson, Glenn C.
    Bray, Mark R.
    BLOOD, 2021, 138
12345